Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes

Endocrine Journal

Volumn 57, Issue 5, 2010, Pages 423-430

  Nakano, Koji ^a,b   Hasegawa, Goji ^b   Fukui, Michiaki ^b   Yamasaki, Masahiro ^b   Ishihara, Kiyoshi ^a   Takashima, Tooru ^a   Kitagawa, Yoshihiro ^c   Fujinami, Aya ^d   Ohta, Mitsuhiro ^d   Hara, Hirokazu ^e   Adachi, Tetsuo ^e   Ogata, Masakazu ^f   Obayashi, Hiroshi ^f   Nakamura, Naoto ^b  

^a Yamashiro Public Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c WEST JAPAN RAILWAY COMPANY   (Japan)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^e GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^f Institute of Bio Response Informatics   (Japan)

Author keywords

Adiponectin; Hepatic insulin resistance; Large VLDL; Lipoprotein subclass particle size; Pioglitazone

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; HEMOGLOBIN A1C; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PATIENT MONITORING; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT RESPONSE;

AGE OF ONSET; ANTILIPEMIC AGENTS; BODY FAT DISTRIBUTION; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; METFORMIN; MIDDLE AGED; PARTICLE SIZE; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 77953630209     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-006     Document Type: Article

References (31)

1. Gerich JE (2003) Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78: 447-456.
2. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: 703-713.
4. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ (2002) Metabolic and additional vascular effects of thiazolidinediones. Drugs 62: 1463-1480.
5. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719.
6. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784-2791.
7. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52: 1364-1370.
8. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12: 413-423.
9. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611.
10. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493-2499.
11. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH (2003) J Clin Endocrinol Metab 88: 1637-1645.
12. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141-147.
13. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T (2006) A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 29: 101-206.
14. Hanefeld M (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes Obes Metab 11: 742-756.
15. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsuzawa Y, Yamashita S (2005) Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 25: 578-584.
16. Okazaki M, Usui S, Fukui A, Kubota I, Tomoike H (2006) Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem 52: 2049-2053.
17. Adachi T, Ohta H, Yamada H, Futenma A, Kato K, Hirano K (1992) Quantitative analysis of extracellular-superoxide dismutase in serum and urine by ELISA with monoclonal antibody. Clin Chim Acta 212: 89-102.
18. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M (2004) Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339: 57-63.
19. Fujinami A, Ohta K, Obayashi H, Fukui M, Hasegawa G, Nakamura N, Kozai H, Imai S, Ohta M (2008) Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 41: 812-817.
20. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S (1983) A novel technique for the determination of body fat by computed tomography. Int J Obes 7: 437-445.
21. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators (2007) Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30: 2458-2464.
22. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52: 453-462.
23. Adiels M, Borén J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25: 1697-1703.
24. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ (2004) Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 176: 49-56.
25. Griffin BA, Packard CJ (1994) Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 5: 200-206.
26. Packard CJ (2003) Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31(Pt 5): 1066-1069.
27. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, Yki-Järvinen H, Borén J (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755-765.
28. Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Borén J (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50: 2356-2365.
29. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174.
30. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585.
31. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2007) Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase. Nat Med 13: 332-339.